Tumor Stroma Area and Other Prognostic Factors in Pancreatic Ductal Adenocarcinoma Patients Submitted to Surgery
- PMID: 36832145
- PMCID: PMC9955223
- DOI: 10.3390/diagnostics13040655
Tumor Stroma Area and Other Prognostic Factors in Pancreatic Ductal Adenocarcinoma Patients Submitted to Surgery
Abstract
Pancreatic ductal adenocarcinoma (PDAC) has a dense stroma, responsible for up to 80% of its volume. The amount of stroma can be associated with prognosis, although there are discrepancies regarding its concrete impact. The aim of this work was to study prognostic factors for PDAC patients submitted to surgery, including the prognostic impact of the tumor stroma area (TSA). A retrospective study with PDAC patients submitted for surgical resection was conducted. The TSA was calculated using QuPath-0.2.3 software. Arterial hypertension, diabetes mellitus, and surgical complications Clavien-Dindo>IIIa are independent risk factors for mortality in PDAC patients submitted to surgery. Regarding TSA, using >1.9 × 1011 µ2 as cut-off value for all stages, patients seem to have longer overall survival (OS) (31 vs. 21 months, p = 0.495). For stage II, a TSA > 2 × 1011 µ2 was significantly associated with an R0 resection (p = 0.037). For stage III patients, a TSA > 1.9 × 1011 µ2 was significantly associated with a lower histological grade (p = 0.031), and a TSA > 2E + 11 µ2 was significantly associated with a preoperative AP ≥ 120 U/L (p = 0.009) and a lower preoperative AST (≤35 U/L) (p = 0.004). Patients with PDAC undergoing surgical resection with preoperative CA19.9 > 500 U/L and AST ≥ 100 U/L have an independent higher risk of recurrence. Tumor stroma could have a protective effect in these patients. A larger TSA is associated with an R0 resection in stage II patients and a lower histological grade in stage III patients, which may contribute to a longer OS.
Keywords: pancreatic cancer; prognosis; stroma; survival; tumor microenvironment.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection.World J Gastroenterol. 2020 Dec 14;26(46):7382-7404. doi: 10.3748/wjg.v26.i46.7382. World J Gastroenterol. 2020. PMID: 33362391 Free PMC article.
-
Clinical significance and predictors of complete or near-complete histological response to preoperative chemoradiotherapy in patients with localized pancreatic ductal adenocarcinoma.Pancreatology. 2021 Dec;21(8):1482-1490. doi: 10.1016/j.pan.2021.08.011. Epub 2021 Aug 24. Pancreatology. 2021. PMID: 34452821
-
Combination of preoperative fibrinogen and D-dimer as a prognostic indicator in pancreatic ductal adenocarcinoma patients undergoing R0 resection.World J Gastrointest Surg. 2021 Mar 27;13(3):279-302. doi: 10.4240/wjgs.v13.i3.279. World J Gastrointest Surg. 2021. PMID: 33796216 Free PMC article.
-
Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.Pancreatology. 2015 Nov-Dec;15(6):674-80. doi: 10.1016/j.pan.2015.09.008. Epub 2015 Oct 3. Pancreatology. 2015. PMID: 26467797
-
Preoperative plasma D-dimer independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing radical resection.World J Surg Oncol. 2021 Jun 9;19(1):166. doi: 10.1186/s12957-021-02281-8. World J Surg Oncol. 2021. PMID: 34107980 Free PMC article.
Cited by
-
The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers.J Exp Clin Cancer Res. 2024 Jul 18;43(1):198. doi: 10.1186/s13046-024-03117-5. J Exp Clin Cancer Res. 2024. PMID: 39020414 Free PMC article. Review.
-
Unraveling the glyco-immunity nexus in pancreatic cancer.Mol Cancer. 2025 Aug 4;24(1):211. doi: 10.1186/s12943-025-02417-4. Mol Cancer. 2025. PMID: 40759948 Free PMC article. Review.
-
Epigenetic regulation of the tumor microenvironment: A leading force driving pancreatic cancer.Pancreatology. 2024 Sep;24(6):878-886. doi: 10.1016/j.pan.2024.07.005. Epub 2024 Jul 15. Pancreatology. 2024. PMID: 39095296 Review.
References
LinkOut - more resources
Full Text Sources
Research Materials